| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
12,296 |
10,326 |
$523K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
5,680 |
4,819 |
$176K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,655 |
1,426 |
$67K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
753 |
601 |
$40K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
987 |
912 |
$29K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
313 |
257 |
$16K |
| M0240 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses |
45 |
37 |
$13K |
| 99215 |
Prolong outpt/office vis |
264 |
232 |
$12K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,032 |
711 |
$12K |
| 36415 |
Collection of venous blood by venipuncture |
2,322 |
1,964 |
$3K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
98 |
64 |
$2K |
| 99205 |
Prolong outpt/office vis |
15 |
12 |
$1K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
31 |
25 |
$1K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12 |
12 |
$986.16 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
160 |
129 |
$818.62 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
93 |
74 |
$760.78 |
| 90686 |
|
84 |
67 |
$613.15 |
| 3074F |
|
1,261 |
955 |
$610.00 |
| 3078F |
|
1,220 |
955 |
$600.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
57 |
34 |
$566.78 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
64 |
37 |
$462.10 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
90 |
65 |
$319.04 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
42 |
33 |
$315.09 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
69 |
52 |
$291.56 |
| 3079F |
|
466 |
381 |
$280.00 |
| 87634 |
|
29 |
27 |
$230.83 |
| 96127 |
|
59 |
52 |
$194.26 |
| 3077F |
|
297 |
236 |
$140.00 |
| 81003 |
|
91 |
85 |
$125.43 |
| 3075F |
|
198 |
172 |
$70.00 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
86 |
57 |
$68.87 |
| 81002 |
|
40 |
32 |
$53.90 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
28 |
24 |
$44.20 |
| 99406 |
|
13 |
13 |
$28.67 |
| Q0240 |
Injection, casirivimab and imdevimab, 600 mg |
28 |
24 |
$0.20 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
1,728 |
1,278 |
$0.00 |
| H0001 |
Alcohol and/or drug assessment |
53 |
40 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
87 |
63 |
$0.00 |
| 99000 |
|
39 |
26 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
16 |
14 |
$0.00 |